Published in J Neurooncol on September 22, 2011
Carcinomatous meningitis: Leptomeningeal metastases in solid tumors. Surg Neurol Int (2013) 2.12
Leptomeningeal metastases in breast cancer. Am J Cancer Res (2013) 1.00
Leptomeningeal metastasis in breast cancer - a systematic review. Oncotarget (2016) 0.97
Survival following gamma knife radiosurgery for brain metastasis from breast cancer. Radiat Oncol (2013) 0.96
Risk factors and survival outcomes in patients with brain metastases from breast cancer. Clin Exp Metastasis (2013) 0.88
Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival. Br J Cancer (2012) 0.88
A case of brain metastases from breast cancer treated with whole-brain radiotherapy and eribulin mesylate. Case Rep Oncol Med (2012) 0.87
The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival. Clin Exp Metastasis (2012) 0.84
Impact of multimodality approach for patients with leptomeningeal metastases from solid tumors. J Korean Med Sci (2014) 0.78
The shifting landscape of metastatic breast cancer to the CNS. Neurosurg Rev (2012) 0.78
Local control of brain metastasis: treatment outcome of focal brain treatments in relation to subtypes. J Breast Cancer (2015) 0.78
Incidence and risk factors for leptomeningeal carcinomatosis in breast cancer patients with parenchymal brain metastases. J Korean Neurosurg Soc (2012) 0.75
Neuroborreliosis Mimicking Leptomeningeal Carcinomatosis in a Patient With Breast Cancer: A Case Report. J Investig Med High Impact Case Rep (2014) 0.75
Clinicopathological Factors Related to the Prognosis of Metastatic Breast Cancer Patients after Development of Brain Metastasis. Breast Care (Basel) (2015) 0.75
Headache in a young woman: leptomeningeal metastasis as the first presentation of underlying breast malignancy. BMJ Case Rep (2015) 0.75
Methods and results of local treatment of brain metastases in patients with breast cancer. Contemp Oncol (Pozn) (2017) 0.75
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med (2011) 12.45
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.93
First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med (2014) 10.91
Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 9.94
Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med (2012) 9.17
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (2012) 8.00
A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet (2007) 7.35
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med (2015) 7.11
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol (2011) 7.10
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol (2012) 5.82
Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial. Lancet Oncol (2010) 5.51
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol (2009) 5.05
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 4.24
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol (2005) 4.03
Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod Pathol (2012) 4.00
Virus-enabled synthesis and assembly of nanowires for lithium ion battery electrodes. Science (2006) 3.87
The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res (2012) 3.80
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol (2013) 3.67
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol (2011) 3.27
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A (2012) 3.06
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol (2012) 3.02
A streamlined platform for high-content functional proteomics of primary human specimens. Nat Methods (2005) 3.00
Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res (2004) 2.90
Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J Natl Cancer Inst (2009) 2.88
Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol (2007) 2.62
FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. Hum Mol Genet (2009) 2.62
Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation (2005) 2.44
Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol (2004) 2.44
Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer (2011) 2.38
Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment. Lung Cancer (2008) 2.37
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet (2013) 2.24
An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys (2005) 2.19
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol (2011) 2.19
Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol (2013) 2.14
Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol (2011) 2.09
Extrapulmonary small-cell carcinoma: a single-institution experience. Jpn J Clin Oncol (2004) 2.02
Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology (2010) 1.98
Survival benefit of gastrectomy ± metastasectomy in patients with metastatic gastric cancer receiving chemotherapy. Gastric Cancer (2011) 1.98
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. Lancet Oncol (2012) 1.98
Genome-wide association study in east Asians identifies novel susceptibility loci for breast cancer. PLoS Genet (2012) 1.91
Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst (2013) 1.90
Endoscopic thyroidectomy using a new bilateral axillo-breast approach. World J Surg (2007) 1.88
Discovery and validation of breast cancer subtypes. BMC Genomics (2006) 1.83
Chemotherapy use and associated factors among cancer patients near the end of life. Oncology (2007) 1.80
Hippocampal and prefrontal projections to the basal amygdala mediate contextual regulation of fear after extinction. J Neurosci (2011) 1.77
Underweight and breast cancer recurrence and death: a report from the Korean Breast Cancer Society. J Clin Oncol (2009) 1.77
Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest (2004) 1.75
Discrepancies among patients, family members, and physicians in Korea in terms of values regarding the withholding of treatment from patients with terminal malignancies. Cancer (2004) 1.71
Primary pulmonary non-Hodgkin's lymphoma. Jpn J Clin Oncol (2004) 1.70
Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res (2011) 1.69